Aprea Therapeutics, Inc.
Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 23 Jul 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 23 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Aprea Therapeutics, Inc. — Overview & Financial Snapshot
Aprea Therapeutics, Inc. (NasdaqCM: APRE) is a Healthcare company, ranked #3,217 of 6,774 companies globally and #1,307 of 4,000 in United States on PositoAI, with a Positivity Score of 20,753. Its market capitalisation is ₹64.37 Cr ($6.82M), P/E ratio is -0.6 and P/B ratio is 0.18. It currently has 2 active red flags (PosiRed) and no yellow flags (PosiYellow) on record.
For financial statements, ratio trends and score history, Go Deep →